Healthy
Conditions
Keywords
Buglossoides arvensis, vegetable oil, omega-3 fatty acids, participants
Brief summary
The effect of various doses of Buglossoides oil on the accrual of eicosapentaenoic acid (EPA) in blood and circulating cells will be investigated.
Interventions
DIETARY_SUPPLEMENTBuglossoides oil
DIETARY_SUPPLEMENTHigh Oleic Sunflower Oil
Sponsors
Réseau de Santé Vitalité Health Network
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Men or non-pregnant women, using an effective form of birth control (such as oral contraceptives, injectable contraceptives or the barrier method such as a intrauterine device (IUD) with a spermicide, a diaphragm with a spermicide, a condom with a spermicide or a sponge with a spermicide) for at least 3 months prior to entry into the study and continuing during participation in the study. 2. 18 to 65 years of age, inclusive. 3. Body mass index (BMI) 18 - 39.9 kg/m2 4. Subject is willing to avoid alcohol consumption for 24h prior to every clinic visit. 5. The subject will not modify smoking habits during supplementation period. 6. No significant medical conditions that in the opinion of the qualified physician, would preclude the subject's participation in the study. 7. Signed informed consent. 8. Willing to follow all study procedures including study visits, fasting blood draws, stable body weight, normal eating habits, current activity level, and compliance with study preparation. 9. Willing to not consume fish, crustaceans and shellfish for the duration of the study.
Exclusion criteria
1. Pregnancy or lactation. Women trying to conceive. Women who will try to conceive who are unwilling to commit to the use of a medically approved form of contraception throughout the study period. Method of contraception must be recorded in the case report file. 2. Individual has a condition the study physician believes would interfere with the participant's ability to provide informed consent, comply with his responsibilities during the study, which might confound the interpretation of the study results or put the person at undue risk. 3. Medical conditions including an active peptic ulcer, inflammatory bowel disease, or gastrointestinal bleeding and any medical condition or prior gastrointestinal surgery that could influence absorption, metabolism or excretion of the study supplement. 4. History or presence of significant, renal, hepatic, gastrointestinal, pulmonary, biliary, neurological or endocrine disorders. 5. History or presence of cancer in the past 2 yrs, except for non-melanoma skin cancers (e.g. basal or squamous cell carcinoma of the skin). 6. Clinically significant abnormal laboratory test results including but not limited to LDL-cholesterol ≥ 4.1mM, triglyceride levels ≥3.95mM, fasting creatinine ≥ 1.5 mg/dL, alanine transaminase or aspartate aminotransferase ≥ 1.5X the upper limit of normal. 7. Currently being treated for angina, arrhythmia and/or congestive heart failure. History of myocardial infarction or stroke. 8. Uncontrolled hypertension (resting systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg). 9. Type 1 or 2 diabetes. Fasting glucose ≥ 100 mg/dL. HbA1c ≥ 6.0. 10. If a smoker, subject smokes no more than 1 pack (20 cigarettes) daily. 11. History (within 12 months) or current alcohol or substance abuse (no more than 14 consumptions per week; 1 consumption= 12 oz beer, 5 oz wine, 1.5 oz distilled spirits). 12. Use of any lipid-altering medications (statins, bile acid sequestrants, cholesterol absorption inhibitors, fibrates, over the counter and prescription formulations of niacin). 13. Unstable use of thyroid medication. Stable, treated hypothyroidism is not an
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma eicosapentaenoic concentration (EPA) | Day 28 | Expressed as μmol/L plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Fasting hematology: neutrophil count | Day 28 | — |
| Fasting hematology: red blood cell count | Day 28 | — |
| Fasting hematology:hemoglobin | Day 28 | — |
| Fasting hematology: hematocrit | Day 28 | — |
| Fasting hematology: platelet count | Day 28 | — |
| Fasting blood lipid profile: triglycerides | Day 28 | — |
| Fasting blood lipid profile: total cholesterol | Day 28 | — |
| Fasting blood lipid profile: low density lipoprotein cholesterol (LDL-c) | Day 28 | — |
| Urinalysis: leukocyte esterase | Day 28 | — |
| Urinalysis: density | Day 28 | — |
| Fasting hematology: white blood cell count | Day 28 | — |
| Urinalysis: nitrites | Day 28 | — |
| Urinalysis: pH | Day 28 | — |
| Urinalysis: protein | Day 28 | — |
| Urinalysis: glucose | Day 28 | — |
| Urinalysis: acetone | Day 28 | — |
| Urinalysis: blood | Day 28 | — |
| Urinalysis: urobilinogen | Day 28 | — |
| Fasting serum chemistry: albumin | Day 28 | — |
| Plasma 20:4n-3 | Day 28 | Expressed as μmol/L plasma |
| Plasma docosapentaenoic acid (DPA) | Day 28 | Expressed as μmol/L plasma |
| Plasma 20:4n-3, EPA and DPA individually as % of total fatty acids | Day 28 | — |
| Mononuclear cell 20:4n-3, EPA and DPA individually as % of total fatty acids | Day 28 | — |
| Fasting serum chemistry: glucose | Day 28 | — |
| Fasting serum chemistry: calcium | Day 28 | — |
| Fasting serum chemistry: sodium | Day 28 | — |
| Fasting serum chemistry: potassium | Day 28 | — |
| Fasting serum chemistry: blood urea nitrogen | Day 28 | — |
| Fasting serum chemistry: creatinine | Day 28 | — |
| Fasting serum chemistry: alkaline phosphatase | Day 28 | — |
| Fasting serum chemistry: aspartate aminotransferase | Day 28 | — |
| Fasting serum chemistry: gamma-glutamyltransferase | Day 28 | — |
| Fasting serum chemistry: total bilirubin | Day 28 | — |
| Fasting serum chemistry: amylase | Day 28 | — |
| Fasting serum chemistry: uric acid | Day 28 | — |
| Fasting blood lipid profile: non-high density lipoprotein-cholesterol (non-HDL-c) | Day 28 | — |
| Fasting blood lipid profile: HDL-c | Day 28 | — |
| Fasting serum chemistry: chloride | Day 28 | — |
| Estimated glomerular filtration rate | Day 28 | — |
| Fasting hematology profile: mean corpuscular volume | Day 28 | — |
| Fasting hematology profile: mean corpuscular hemoglobin | Day 28 | — |
| Fasting hematology profile: mean corpuscular hemoglobin concentration | Day 28 | — |
| Fasting hematology profile: red cell distribution width | Day 28 | — |
| Fasting hematology profile: mean platelet volume | Day 28 | — |
| Fasting hematology profile: lymphocyte concentration | Day 28 | — |
| Fasting hematology profile: monocyte count | Day 28 | — |
| Fasting hematology profile: eosinophil count | Day 28 | — |
| Fasting hematology profile: basophil count | Day 28 | — |
| Fasting hematology profile: Immature granulocytes count | Day 28 | — |
| Fasting hematology profile: immature granulocytes (% white blood cell (WBC)) | Day 28 | — |
| Fasting hematology profile: neutrophil (% WBC) | Day 28 | — |
| Fasting hematology profile: lymphocyte (% WBC) | Day 28 | — |
| Fasting hematology profile: monocytes (% WBC) | Day 28 | — |
| Fasting hematology profile: eosinophil (% WBC) | Day 28 | — |
| Fasting hematology profile: basophil (% WBC) | Day 28 | — |
| Urinalysis: appearance | Day 28 | — |
Other
| Measure | Time frame |
|---|---|
| Cytokine production following ex vivo stimulation: interleukin-1beta | Day 28 |
| Cytokine production following ex vivo stimulation: interleukin-6 | Day 28 |
| Cytokine production following ex vivo stimulation: interleukin-8 | Day 28 |
| Cytokine production following ex vivo stimulation: interleukin-10 | Day 28 |
| Cytokine production following ex vivo stimulation: interleukin-17A | Day 28 |
| Cytokine production following ex vivo stimulation: interleukin-23 | Day 28 |
| Cytokine production following ex vivo stimulation: monocyte chemoattractant protein-1 | Day 28 |
| Cytokine production following ex vivo stimulation: tumor necrosis factor-alpha | Day 28 |
| Cytokine production following ex vivo stimulation: interferon-gamma | Day 28 |
Countries
Canada
Outcome results
None listed